{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:43:27Z","timestamp":1791845007626,"version":"4.3.4"},"reference-count":81,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"General Hospital of Ningxia Medical University [2023]","award":["394 2023"],"award-info":[{"award-number":["394 2023"]}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis (MS) are both inflammatory demyelinating diseases of the central nervous system, sharing many similarities in clinical manifestations. However, they differ significantly in terms of etiology, pathological mechanisms, treatment, and prognosis. Since early clinical differentiation can be challenging, achieving an accurate diagnosis at the initial stage of disease onset is particularly critical. Therefore, a thorough analysis of patients\u2019 clinical characteristics is of great importance in assisting clinicians with early diagnosis and treatment, ultimately contributing to improved patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical data were collected for patients who were first diagnosed with NMOSD or MS at the General Hospital and the Cardiovascular and Cerebrovascular Hospital of Ningxia Medical University between January 2018 and January 2022. Collected information included demographic data, past medical history, initial clinical symptoms, physical examination findings, laboratory tests, imaging studies, and three types of evoked potentials. Patients were followed up for relapse during remission, presence of residual symptoms, medication use, and scores on the Extended Disability Status Scale (EDSS). The clinical characteristics of the two diseases were summarized and the results subjected to statistical analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This study conducted a comparative analysis across multiple indicators, comprehensively revealing significant differences in the clinical characteristics of NMOSD and MS. The results showed that the proportion of female patients was significantly higher in the NMOSD group (86.2%) compared with the MS group (69.0%), with a statistically significant difference (\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.035). In terms of clinical manifestations, NMOSD patients more frequently presented with comorbid autoimmune diseases, initial symptoms, and neurological signs at admission, all of which were more severe and common than in MS patients, with statistically significant differences. The severity of neurological dysfunction in NMOSD patients during the acute phase was also markedly greater than that observed in MS patients, as confirmed by comparisons of the EDSS scores. Laboratory examinations further demonstrated fundamental differences between NMOSD and MS in cerebrospinal fluid characteristics, specific antibodies, and other serological markers, providing important evidence for differential diagnosis. In addition, imaging and electrophysiological findings indicated that MS lesions were predominantly located in the brain, whereas NMOSD lesions mainly involved the optic nerve and spinal cord. Notably, NMOSD patients exhibited more extensive spinal cord involvement and more frequent impairment of the visual pathway.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although NMOSD and MS share many similarities in clinical symptoms, they differ substantially in their fundamental characteristics, as reflected in demographic features, clinical manifestations, laboratory and imaging findings, as well as prognosis. Compared with MS, NMOSD patients are typically older at disease onset, have a higher proportion of females, and experience more frequent relapses and greater disability. In terms of imaging, MS lesions are predominantly distributed in the brain, whereas NMOSD mainly involves the optic nerve and spinal cord. Therefore, early differentiation between the two diseases in clinical practice is essential for developing targeted treatment strategies and ultimately improving patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1718736","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:27:49Z","timestamp":1768886869000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Differential diagnosis between NMOSD and MS: a retrospective study based on clinical and imaging features"],"prefix":"10.3389","volume":"17","author":[{"given":"Ya-Nan","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Geriatrics and Specialty Medicine, General Hospital of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurophysiology, Ningbo Medical Center Li Huili Hospital","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Rong","family":"Ma","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Geriatrics and Specialty Medicine, General Hospital of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Ding","sequence":"additional","affiliation":[{"name":"Emergency Department, General Hospital of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Qiu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Geriatrics and Specialty Medicine, General Hospital of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1002\/ana.410360704","article-title":"Natural history of multiple sclerosis","volume":"36","author":"Weinshenker","year":"1994","journal-title":"Ann Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic\u2019s syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/088307389601100220","article-title":"Neuromyelitis Optica in childhood: case report with sequential MRI findings","volume":"11","author":"Davis","year":"1996","journal-title":"J Child Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"118842","DOI":"10.1016\/j.jns.2021.118842","article-title":"Neuromyelitis optica spectrum disorders in the elderly","volume":"429","author":"Boudanga","year":"2021","journal-title":"J Neurol Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","article-title":"A secondary progressive clinical course is uncommon in neuromyelitis optica","volume":"68","author":"Wingerchuk","year":"2007","journal-title":"Neurology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1136\/jnnp-2023-332663","article-title":"Long-term disability progression in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a retrospective analysis of 101 patients","volume":"95","author":"Uzawa","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"102750","DOI":"10.1016\/j.msard.2021.102750","article-title":"Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy","volume":"49","author":"Takai","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11940-021-00667-3","article-title":"New therapeutic landscape in neuromyelitis optica","volume":"23","author":"Tugizova","year":"2021","journal-title":"Curr Treat Options Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"Eur J Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5603\/pjnns.100945","article-title":"Update on diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) \u2014 recommendations of section of multiple sclerosis and neuroimmunology of polish neurological society","volume":"59","author":"Zakrzewska-Pniewska","year":"2025","journal-title":"Neurol Neurochir Pol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1212\/WNL.58.8_suppl_4.S3","article-title":"Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis","volume":"58","author":"Dhib-Jalbut","year":"2002","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.expneurol.2014.03.009","article-title":"Th17 cells in central nervous system autoimmunity","volume":"262","author":"Sie","year":"2014","journal-title":"Exp Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.ncl.2016.06.016","article-title":"Epidemiology of multiple sclerosis","volume":"34","author":"Howard","year":"2016","journal-title":"Neurol Clin"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e0011923","DOI":"10.1128\/mmbr.00119-23","article-title":"Multiple sclerosis and infection: history, EBV, and the search for mechanism","volume":"89","author":"SoRelle","year":"2025","journal-title":"Microbiol Mol Biol Rev"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000227277","article-title":"Interferon-beta(1b) treatment in neuromyelitis optica","volume":"62","author":"Tanaka","year":"2009","journal-title":"Eur Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jns.2006.10.008","article-title":"Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination","volume":"252","author":"Warabi","year":"2007","journal-title":"J Neurol Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/WCO.0000000000001128","article-title":"Optic neuritis: current challenges in diagnosis and management","volume":"36","author":"Benard-Seguin","year":"2022","journal-title":"Curr Opin Neurol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e363","DOI":"10.1212\/NXI.0000000000000363","article-title":"Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS","volume":"4","author":"Gahlen","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1056\/NEJMct1101691","article-title":"Fingolimod for multiple sclerosis","volume":"366","author":"Pelletier","year":"2012","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev-pharmtox-010818-021358","article-title":"Fingolimod: lessons learned and new opportunities for treating multiple sclerosis and other disorders","volume":"59","author":"Chun","year":"2019","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2011","journal-title":"Mult Scler J"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1115120","DOI":"10.3389\/fimmu.2023.1115120","article-title":"Case report: severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder","volume":"14","author":"Lin","year":"2023","journal-title":"Front Immunol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of NMO: a systematic review","volume":"96","author":"Papp","year":"2020","journal-title":"Neurology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s10072-023-06617-y","article-title":"Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): a systematic review and meta-analysis","volume":"44","author":"Bagherieh","year":"2023","journal-title":"Neurol Sci"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e00539","DOI":"10.1016\/j.neurot.2025.e00539","article-title":"The epidemiology, pathology and pathogenesis of MS: therapeutic implications","volume":"22","author":"Goodin","year":"2025","journal-title":"Neurotherapeutics"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"375","DOI":"10.5603\/pjnns.103955","article-title":"Epidemiology of multiple sclerosis: global trends, regional differences, and clinical implications","volume":"59","author":"Kapica-Topczewska","year":"2025","journal-title":"Neurol Neurochir Pol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1007\/s00415-024-12452-8","article-title":"Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis","volume":"271","author":"Arnett","year":"2024","journal-title":"J Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"933415","DOI":"10.3389\/fimmu.2022.933415","article-title":"Sex bias in multiple sclerosis and neuromyelitis optica spectrum disorders: how it influences clinical course, MRI parameters and prognosis","volume":"13","author":"Nytrova","year":"2022","journal-title":"Front Immunol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/ana.21978","article-title":"Primary infection with the Epstein-Barr virus and risk of multiple sclerosis","volume":"67","author":"Levin","year":"2010","journal-title":"Ann Neurol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1093\/brain\/awp312","article-title":"Does Epstein-Barr virus infection in the brain drive the development of multiple sclerosis?","volume":"132","author":"Pender","year":"2009","journal-title":"Brain"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jns.2010.10.013","article-title":"A serological analysis of viral and bacterial infections associated with neuromyelitis optica","volume":"300","author":"Koga","year":"2011","journal-title":"J Neurol Sci"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jaut.2009.09.013","article-title":"The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes","volume":"34","author":"Sellner","year":"2010","journal-title":"J Autoimmun"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/jnnp-2014-308095","article-title":"Epstein-Barr virus persistence and reactivation in neuromyelitis optica","volume":"86","author":"Masuda","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jneuroim.2018.06.017","article-title":"Helicobacter pylori infection and demyelinating disease of the central nervous system","volume":"329","author":"Kira","year":"2019","journal-title":"J Neuroimmunol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1007\/s10072-024-07328-8","article-title":"Helicobacter pylori infection and risk of multiple sclerosis: an updated meta-analysis","volume":"45","author":"Thapa","year":"2024","journal-title":"Neurol Sci"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1007\/s10072-024-07424-9","article-title":"A potential effect of active Helicobacter pylori infection on the risk of multiple sclerosis","volume":"45","author":"Kountouras","year":"2024","journal-title":"Neurol Sci"},{"key":"ref44","first-page":"2238","author":"Klawiter","year":"2017"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.3389\/fneur.2019.01070","article-title":"Pregnancy-related immune changes and demyelinating diseases of the central nervous system","volume":"10","author":"Qiu","year":"2019","journal-title":"Front Neurol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1212\/WNL.0000000000002208","article-title":"Pregnancy outcomes in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"86","author":"Nour","year":"2016","journal-title":"Neurology"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.4049\/jimmunol.1301483","article-title":"Neuromyelitis Optica IgG causes placental inflammation and Fetal death","volume":"191","author":"Saadoun","year":"2013","journal-title":"J Immunol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1007\/s13311-017-0562-7","article-title":"Pregnancy: effect on multiple sclerosis, treatment considerations, and breastfeeding","volume":"14","author":"Voskuhl","year":"2017","journal-title":"Neurotherapeutics"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1429405","DOI":"10.3389\/fimmu.2024.1429405","article-title":"Protein-a immunoadsorption combined with immunosuppressive treatment in refractory primary Sj\u00f6gren\u2019s syndrome coexisting with NMOSD: a case report and literature review","volume":"15","author":"Fan","year":"2024","journal-title":"Front Immunol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"e14973","DOI":"10.1111\/1756-185X.14973","article-title":"Neuromyelitis optica spectrum disorders (NMOSD) and systemic lupus erythematosus (SLE): dangerous duo","volume":"27","author":"Abou Raya","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"400","DOI":"10.34172\/aim.28804","article-title":"Neuromyelitis in a patient with rheumatoid arthritis: a case report","volume":"27","author":"Qiang","year":"2024","journal-title":"Arch Iran Med"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1007\/s10165-011-0572-y","article-title":"Semiquantitative measurement of aquaporin-4 antibodies as a possible surrogate marker of neuromyelitis optica spectrum disorders with systemic autoimmune diseases","volume":"22","author":"Katsumata","year":"2011","journal-title":"Mod Rheumatol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"e71500","DOI":"10.1371\/journal.pone.0071500","article-title":"The major brain endocannabinoid 2-AG controls neuropathic pain and mechanical hyperalgesia in patients with neuromyelitis Optica","volume":"8","author":"Pellkofer","year":"2013","journal-title":"PLoS One"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/135245859900500307","article-title":"Sensory symptoms of multiple sclerosis: a hidden reservoir of morbidity","volume":"5","author":"Rae-Grant","year":"1999","journal-title":"Mult Scler J"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/13524585241292797","article-title":"How to avoid missing a diagnosis of neuromyelitis optica spectrum disorder","volume":"31","author":"Contentti","year":"2024","journal-title":"Mult Scler J"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1212\/WNL.0b013e318229e694","article-title":"Pain in neuromyelitis optica and its effect on quality of life","volume":"77","author":"Kanamori","year":"2011","journal-title":"Neurology"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2377-13-33","article-title":"Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study","volume":"13","author":"Asgari","year":"2013","journal-title":"BMC Neurol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.neurad.2008.12.008","article-title":"MRI of the spinal cord in neuromyelitis optica and recurrent longitudinal extensive myelitis","volume":"36","author":"Cassinotto","year":"2009","journal-title":"J Neuroradiol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1007\/s10072-024-07895-w","article-title":"Review of atypical optic neuritis","volume":"46","author":"\u017dori\u0107","year":"2024","journal-title":"Neurol Sci"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12967-025-06105-1","article-title":"From diagnosis to treatment: exploring the mechanisms underlying optic neuritis in multiple sclerosis","volume":"23","author":"Tong","year":"2025","journal-title":"J Transl Med"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/WCO.0000000000001335","article-title":"The atypical faces of optic neuritis: neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"38","author":"Poonja","year":"2024","journal-title":"Curr Opin Neurol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jns.2015.05.013","article-title":"Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis","volume":"355","author":"Mealy","year":"2015","journal-title":"J Neurol Sci"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","article-title":"Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures","volume":"306","author":"Jarius","year":"2011","journal-title":"J Neurol Sci"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult Scler J"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1177\/1352458516663853","article-title":"The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates","volume":"23","author":"Hamid","year":"2016","journal-title":"Mult Scler J"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1093\/brain\/awz144","article-title":"Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines","volume":"142","author":"Filippi","year":"2019","journal-title":"Brain"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1148\/rg.2018170141","article-title":"Neuromyelitis Optica Spectrum disorders: Spectrum of MR imaging findings and their differential diagnosis","volume":"38","author":"Dutra","year":"2018","journal-title":"Radiographics"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1212\/WNL.0b013e318214332c","article-title":"Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications","volume":"76","author":"Popescu","year":"2011","journal-title":"Neurology"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/nyas.12794","article-title":"Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later","volume":"1366","author":"Pittock","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorder","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1177\/1352458515591069","article-title":"Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging","volume":"22","author":"Pekcevik","year":"2015","journal-title":"Mult Scler J"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jns.2016.11.035","article-title":"The characteristics of spinal imaging in different types of demyelinating diseases","volume":"372","author":"Dumrikarnlert","year":"2017","journal-title":"J Neurol Sci"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrneurol.2015.80","article-title":"Spinal cord MRI in multiple sclerosis\u2014diagnostic, prognostic and clinical value","volume":"11","author":"Kearney","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1177\/1352458513503053","article-title":"Visual evoked potentials in neuromyelitis optica and its spectrum disorders","volume":"20","author":"Ringelstein","year":"2013","journal-title":"Mult Scler J"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jns.2016.02.060","article-title":"Evoked potentials are useful for diagnosis of neuromyelitis optica spectrum disorder","volume":"364","author":"Ohnari","year":"2016","journal-title":"J Neurol Sci"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1136\/bjophthalmol-2018-312231","article-title":"Peripapillary and parafoveal vascular network assessment by optical coherence tomography angiography in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders","volume":"103","author":"Huang","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/1352458514567216","article-title":"Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography","volume":"21","author":"Bennett","year":"2015","journal-title":"Mult Scler J"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1185\/03007995.2013.787979","article-title":"Consensus guidelines for the diagnosis and treatment of multiple sclerosis","volume":"29","author":"Yamout","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1718736\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:37:41Z","timestamp":1771918661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1718736\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":81,"alternative-id":["10.3389\/fneur.2026.1718736"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1718736","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"article-number":"1718736"}}